Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil with or without bevacizumab in refractory metastatic colorectal cancer
2020-001976-14Phase 3Completed
- Sponsor
- Servier
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Trifluridine/tipiracil + bevacizumab with Trifluridine/tipiracil monotherapy (2 arms). Primary endpoint: Overall Survival. Started Jul 2020; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-001976-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001976-14.